ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Kathie Bishop - SVP and Head, Rare Disease & External Innovation

Srdjan Stankovic - President

Stephen Davis - CEO & Director

Mark Johnson - VP, IR

Brendan Teehan - EVP, COO & Head of Commercial

Mark Schneyer - EVP & CFO

Conference Call Participants

Jay Olson - Oppenheimer

Marc Goodman - SVB Securities

Tazeen Ahmad - Bank of America Merrill Lynch

Ritu Baral - Cowen and Company

Neena Garg - Citigroup

Gregory Renza - RBC Capital Markets

Sumant Kulkarni - Canaccord Genuity

Charles Duncan - Cantor Fitzgerald & Co.

Eddie Hickman - Guggenheim Securities

Operator

Good day, ladies and gentlemen, and welcome to the ACADIA Pharmaceuticals Second Quarter 2022 Financial Results Conference Call. [Operator Instructions].

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Mr. Mark Johnson, Vice President of Investor Relations at ACADIA. Please go ahead, sir.

Mark Johnson

Thank you. Good afternoon, and thank you for joining us on today's call of ACADIA's Second Quarter 2020 Financial Results. Joining me on the call today from ACADIA are Steve Davis, our Chief Executive Officer; will provide an overview of our second quarter performance and a review of our business; Mark Schneyer, our Chief Financial Officer, will discuss our financial results and guidance; Brendan Teehan, our Chief Operating Officer, Head of Commercial; will provide updates on our commercial performance; and Kathie Bishop, our Chief Scientific Officer and Head of Rare Disease, will provide an overview on trofinetide. Stankovic, our President, will then discuss our pipeline progress before turning it back to Steve for final remarks and opening the call up for your questions.

I would also like to point out that we are using supplemental slides, which are available on the Events and Presentations section of our website. Before we proceed, I would first like to remind you that during our call today, we'll be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including goals, expectations, plans, prospects, growth potential, timing of events or results are based on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially. These factors and other risks associated with our business can be found in our filings made with the SEC. You are cautioned not to place under reliance on these forward-looking statements, which are made only as of today's date. I'll now turn the call over to Steve.